APH - Alliance Pharma plc
LSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Chippenham,
United Kingdom
Type: Equity
APH price evolution
APH
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3130.3 | $2855.5 | $2501.4 | $2618.4 |
| Inventory | $2578.8 | $2398.8 | $2152.9 | $2167.1 |
| Total current assets | $7772.8 | $6971.8 | $7041.7 | $6835.3 |
| Long term investments | ||||
| Property, plant & equipment | $1670.9 | $1534 | $1311.6 | $1314.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $19585.6 | $18586.8 | $16722.5 | $16526.4 |
| Current liabilities | ||||
| Accounts payable | $1763 | $1521.4 | $1264.7 | $1350.9 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3901.7 | $3455.8 | $3423.1 | $3152.7 |
| Long term debt | $5081 | $5035.3 | $3556.9 | $3983.5 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $10133.1 | $9606.7 | $8041 | $8179.9 |
| Shareholders' equity | ||||
| Retained earnings | $6750.5 | $6352 | $6163.5 | $5921.1 |
| Other shareholder equity | -$519.9 | -$648.5 | -$602.9 | -$533.6 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.06 | $28.9 | ||
| Short term investments | ||||
| Net receivables | $2618.4 | $2631.3 | $27.72 | $24.22 |
| Inventory | $2167.1 | $2093.6 | $21.07 | $22.92 |
| Total current assets | $6835.3 | $6479.1 | $81.02 | $77.24 |
| Long term investments | ||||
| Property, plant & equipment | $1314.7 | $1204.3 | $4.46 | $4.49 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $16526.4 | $15326.2 | $503.49 | $508.85 |
| Current liabilities | ||||
| Accounts payable | $1350.9 | $1309.1 | $8.34 | $11.28 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3152.7 | $2676.1 | $40.58 | $30.19 |
| Long term debt | $3983.5 | $4575 | $116.06 | $138.33 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $8179.9 | $8310.6 | $221 | $227.9 |
| Shareholders' equity | ||||
| Retained earnings | $5921.1 | $4979.4 | $116.42 | $117.7 |
| Other shareholder equity | -$533.6 | -$535 | $9.36 | $7.28 |
| Total shareholder equity | $282.49 | $280.96 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4038.8 | $3609.7 | $3327.5 | |
| Cost of revenue | ||||
| Gross Profit | $1356.9 | $1213.1 | $1100.4 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $492 | $444.3 | $394.1 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $166.1 | $135.1 | $146.3 | |
| Interest expense | -$55.7 | -$56.3 | -$35 | |
| Net income | ||||
| Net income | $604.4 | $524.8 | $514.5 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12554.7 | $12623 | $163.21 | $129.8 |
| Cost of revenue | $53.76 | $46.98 | ||
| Gross Profit | $4084.1 | $4028.2 | $109.45 | $82.82 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $60.63 | $44.61 | ||
| Total operating expenses | $1489.9 | $1420.9 | $125.16 | $100.13 |
| Operating income | $38.05 | $29.67 | ||
| Income from continuing operations | ||||
| EBIT | $38.05 | $29.67 | ||
| Income tax expense | $509.3 | $550.6 | $10.84 | $4.99 |
| Interest expense | -$139.5 | -$128.4 | -$3.65 | -$2.66 |
| Net income | ||||
| Net income | $1928 | $1902.3 | $7.32 | $8.03 |
| Income (for common shares) | $7.32 | $8.03 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2398.2 | -$2195.7 | -$17 | -$1393.7 |
| Financing activities | ||||
| Dividends paid | -$396.2 | -$263.8 | -$131.7 | -$500.6 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $515.8 | $743.4 | -$176.2 | -$1012.4 |
| Effect of exchange rate | $2.8 | -$33.8 | -$24.2 | -$20.7 |
| Change in cash and equivalents | $88 | -$222.5 | $382.1 | $101.9 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $7.32 | $8.03 | ||
| Operating activities | ||||
| Depreciation | $8.74 | $8.91 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $38.66 | $41.57 | ||
| Investing activities | ||||
| Capital expenditures | -$1.53 | -$4.61 | ||
| Investments | ||||
| Total cash flows from investing | -$1393.7 | -$731.1 | -$4.6 | -$85.86 |
| Financing activities | ||||
| Dividends paid | -$500.6 | -$477.4 | -$8.6 | -$2.84 |
| Sale and purchase of stock | ||||
| Net borrowings | -$23.51 | $60.17 | ||
| Total cash flows from financing | -$1012.4 | -$1196.7 | -$34.34 | $55.75 |
| Effect of exchange rate | -$20.7 | -$70.8 | $0.45 | -$0.38 |
| Change in cash and equivalents | $101.9 | $176 | $0.16 | $11.07 |
News
Fundamentals
| Market cap | $73.88B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.21B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 26.24% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.99 |
| Quick ratio | 1.33 |